» Articles » PMID: 39446300

Molecular Indicator for Distinguishing Multi-drug-Resistant Tuberculosis from Drug Sensitivity Tuberculosis and Potential Medications for Treatment

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2024 Oct 24
PMID 39446300
Authors
Affiliations
Soon will be listed here.
Abstract

The issue of multi-drug-resistant tuberculosis (MDR-TB) presents a substantial challenge to global public health. Regrettably, the diagnosis of drug-resistant tuberculosis (DR-TB) frequently necessitates an extended period or more extensive laboratory resources. The swift identification of MDR-TB poses a particularly challenging endeavor. To identify the biomarkers indicative of multi-drug resistance, we conducted a screening of the GSE147689 dataset for differentially expressed genes (DEGs) and subsequently conducted a gene enrichment analysis. Our analysis identified a total of 117 DEGs, concentrated in pathways related to the immune response. Three machine learning methods, namely random forest, decision tree, and support vector machine recursive feature elimination (SVM-RFE), were implemented to identify the top 10 genes according to their feature importance scores. A4GALT and S1PR1, which were identified as common genes among the three methods, were selected as potential molecular markers for distinguishing between MDR-TB and drug-susceptible tuberculosis (DS-TB). These markers were subsequently validated using the GSE147690 dataset. The findings suggested that A4GALT exhibited area under the curve (AUC) values of 0.8571 and 0.7121 in the training and test datasets, respectively, for distinguishing between MDR-TB and DS-TB. S1PR1 demonstrated AUC values of 0.8163 and 0.5404 in the training and test datasets, respectively. When A4GALT and S1PR1 were combined, the AUC values in the training and test datasets were 0.881 and 0.7551, respectively. The relationship between hub genes and 28 immune cells infiltrating MDR-TB was investigated using single sample gene enrichment analysis (ssGSEA). The findings indicated that MDR-TB samples exhibited a higher proportion of type 1 T helper cells and a lower proportion of activated dendritic cells in contrast to DS-TB samples. A negative correlation was observed between A4GALT and type 1 T helper cells, whereas a positive correlation was found with activated dendritic cells. S1PR1 exhibited a positive correlation with type 1 T helper cells and a negative correlation with activated dendritic cells. Furthermore, our study utilized connectivity map analysis to identify nine potential medications, including verapamil, for treating MDR-TB. In conclusion, our research identified two molecular indicators for the differentiation between MDR-TB and DS-TB and identified a total of nine potential medications for MDR-TB.

References
1.
Zumla A, Nahid P, Cole S . Advances in the development of new tuberculosis drugs and treatment regimens. Nat Rev Drug Discov. 2013; 12(5):388-404. DOI: 10.1038/nrd4001. View

2.
Chiang C, Centis R, Migliori G . Drug-resistant tuberculosis: past, present, future. Respirology. 2010; 15(3):413-32. DOI: 10.1111/j.1440-1843.2010.01738.x. View

3.
Alsayed S, Gunosewoyo H . Tuberculosis: Pathogenesis, Current Treatment Regimens and New Drug Targets. Int J Mol Sci. 2023; 24(6). PMC: 10049048. DOI: 10.3390/ijms24065202. View

4.
Mok J, Lee M, Kim D, Kim J, Jhun B, Jo K . 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial.... Lancet. 2022; 400(10362):1522-1530. DOI: 10.1016/S0140-6736(22)01883-9. View

5.
Sharma A, Chhabra H, Mahajan R, Chabra T, Batra S . Magnetic Resonance Imaging and GeneXpert: A Rapid and Accurate Diagnostic Tool for the Management of Tuberculosis of the Spine. Asian Spine J. 2016; 10(5):850-856. PMC: 5081319. DOI: 10.4184/asj.2016.10.5.850. View